Products for Research Use Only
RegisterLogin

UC2288

CAT: 0804-HY-112780-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112780-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
UC2288 is a potent and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib. UC2288 potently inhibits cancer cell growth by inducing apoptosis. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM[1].
CAS Number
1394011-91-6
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; MDM-2/p53
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/uc2288.html
Purity
99.82
Solubility
DMSO : 50 mg/mL (ultrasonic) |Ethanol : 12.5 mg/mL (ultrasonic)
Smiles
O=C(N[C@H]1CC[C@H](OC2=NC=C(C(F)(F)F)C=C2)CC1)NC3=CC=C(Cl)C(C(F)(F)F)=C3
Molecular Formula
C20H18ClF6N3O2
Molecular Weight
481.82
Precautions
H302, H315, H319, H335
References & Citations
[1]Hiromi I Wettersten, et al. A Novel p21 Attenuator Which Is Structurally Related to Sorafenib. Cancer Biol Ther. 2013 Mar;14 (3) :278-85.|[2]Romi Gupta, et al. Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proc Natl Acad Sci U S A. 2014 Jul 29;111 (30) :E3062-71.|[3]Jun Hyung Im, et al. p21 inhibitor UC2288 ameliorates MPTP induced Parkinson’s disease progression through inhibition of oxidative stress and neuroinammation. Translational Medicine.Neurobiology of Disease
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
C01538-5mgUC2288

Popular Products